Adverse Drug Reactions of Different Brands of Ceftazidime Injection

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00173901

Enrollment

536

Registered

2005-09-15

Start date

2001-03-31

Completion date

2002-04-30

Last updated

2005-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

ceftazidime, safety, infection

Brief summary

The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.

Detailed description

Ceftazidime is a third generation cephalosporins that should be reserved for severe bacterial infections. Substitution of the brand ceftazidime with a generic ceftazidime raised some concerns. The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.

Interventions

DRUGceftazidime

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

1 Years to 95 Years

Healthy volunteers

Inclusion criteria

* patients in surgical intensive care unit who require ceftazidime treatment

Exclusion criteria

* less than 1 year old

Design outcomes

Primary

Measure	Time frame
The adverse drug reactions of ceftazidime	—

Secondary

Measure	Time frame
The effectiveness of ceftazidime	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026